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Abstract
Background: High throughput sequencing-by-synthesis is an emerging technology that allows the
rapid production of millions of bases of data. Although the sequence reads are short, they can
readily be used for re-sequencing. By re-sequencing the mRNA products of a cell, one may rapidly
discover polymorphisms and splice variants particular to that cell.
Results: We present the utility of massively parallel sequencing by synthesis for profiling the
transcriptome of a human prostate cancer cell-line, LNCaP, that has been treated with the
synthetic androgen, R1881. Through the generation of approximately 20 megabases (MB) of EST
data, we detect transcription from over 10,000 gene loci, 25 previously undescribed alternative
splicing events involving known exons, and over 1,500 high quality single nucleotide discrepancies
with the reference human sequence. Further, we map nearly 10,000 ESTs to positions on the
genome where no transcription is currently predicted to occur. We also characterize various
obstacles with using sequencing by synthesis for transcriptome analysis and propose solutions to
these problems.
Conclusion: The use of high-throughput sequencing-by-synthesis methods for transcript profiling
allows the specific and sensitive detection of many of a cell's transcripts, and also allows the
discovery of high quality base discrepancies, and alternative splice variants. Thus, this technology
may provide an effective means of understanding various disease states, discovering novel targets
for disease treatment, and discovery of novel transcripts.
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Background
Large-scale characterization of mRNA populations has
been approached through the generation of expressed
sequence tags (ESTs), where single-pass sequencing reads
are derived from cDNA clones [1,2]. This approach has
proven to be extremely flexible in providing rapid identi-
fication of gene sequences, novel and alternatively spliced
genes and for the annotation of genomic sequences [3].
Currently, over 30 million ESTs have been deposited into
the public repository for expressed sequences, dbEST [4].
A drawback of this approach is the cost of generating
sequencing reads, which, although continuing to decline,
has dictated the ability for deep expression profiling of a
given sample or tissue. Currently, the largest number of
ESTs from a single tissue is 69,258, derived from pancre-
atic islet cells, and the median number for human EST
datasets is 876. If a eukaryotic cell is estimated to contain
approximately 3 × 105 mRNA molecules [5], then it is
clear that deep sampling and quantization of specific
mRNA populations is yet to be achieved through tradi-
tional EST sequencing. High sequencing costs combined
with high sequence redundancy rates has led to normali-
zation of cDNA libraries, though significantly improving
the ability to derive novel transcript sequences, eliminates
the utility of the EST data for any quantitative assessment
of transcript abundance [6,7].
To address the use of mRNA sequencing to quantitatively
assess transcript abundance the Serial Analysis of Gene
Expression (SAGE) methodology was developed [5]. This
approach provided restriction enzyme defined tags, ini-
tially fourteen base pairs in length, to be extracted from
cDNA molecules. These are concatenated and subjected to
single-pass sequencing, allowing a number of transcripts,
typically 20–35 [8], to be identified in a single sequencing
read. However, a few disadvantages remain with the tech-
nique: a number of transcripts lack the appropriate
anchoring restriction tags to generate a SAGE tag and due
to the relatively short sequences generated, usually 5–15%
of tags will not map unambiguously to any gene locus [9].
As the SAGE tag is also expected to be derived from the 3'
most anchoring restriction site, the ability of this tech-
nique to investigate transcript structure and splice variants
is limited.
We report here on the application of a massively parallel
sequencing approach utilizing sequencing-by-synthesis
[10] as an efficient approach to generate ESTs. On
genomic DNA, this approach has been shown to generate
over 200,000 DNA sequences in a single machine run
with an average read length of 110 base pairs [10], which
is significantly shorter than those typically generated
through Sanger-based capillary array electrophoresis
sequencing. Using sequencing-by-synthesis random shot-
gun sequencing we hypothesize that these approaches will
provide not only a quantitative measure of transcript
abundance but also a survey of splice-variants within an
mRNA population. As this approach does not require the
cloning of the cDNA, it will also not be influenced by
biases introduced by bacterial host-associated cloning
bias.
We have chosen to perform experiments on the LNCaP
human prostate cancer cell line [11] stimulated with syn-
thetic androgen because it represents a well studied exper-
imental resource and is a significant model for the study
of prostate cancer.
Results and discussion
A total of 181,279 ESTs were obtained which passed the
default quality thresholds as determined by the manufac-
turer (454 Life Sciences Corporation, USA). A summary of
the analysis of the ESTs is presented in Table 1. Initially,
low quality bases were trimmed from the EST ends using
trim2 [12] and the resulting sequences, with an average,
minimum and maximum length of 102, 41, and 302 bp,
respectively, were compared to the known and predicted
human transcriptome [3]. 140,906 (77.7%) sequences
matched directly by BLAST [13] to a specific human tran-
script with a p-value less than 9 × 10-7, while 40,373
(22.3%) of the sequences did not match with any known
human transcribed sequence and hence potentially iden-
tify novel transcripts at this relatively high stringency. The
140,906 ESTs mapping to a known transcript cover 1.2
MB of the annotated human transcriptome and are avail-
able through dbEST [14].
An histogram of the abundance of transcripts from anno-
tated gene loci is shown in Figure 1. The ten most abun-
dant transcripts are shown in Table 2. Further, we
Table 1: Summary analysis of EST to human transcriptome/genome mapping
Map Type Count
ESTs mapping to the human transcriptome (p ≤ 9 × 10-7) 140,906
ESTs mapping to the human genome and overlapping with a processed transcript 1261
ESTs which map to a transcribed region 8,221
ESTs which map to the human Genome alone 9,482
ESTs not correlating with the human genome (p ≤ 9 × 10-5)2 0 , 9 8 1
Total 181,279BMC Genomics 2006, 7:246 http://www.biomedcentral.com/1471-2164/7/246
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collected all genes detected in our library which are
described by Ensembl as either being involved in cancer or
expressed in the prostate and have made these available as
a supplementary table [see Additional file 1]. Of the 9,173
loci for which transcription was detected (BLAST p ≤ 9 ×
10-7) 2,199 were observed with a single EST sequence.
Lowering the BLAST p-value to 0.05 allows 152,544 ESTs
to map to 10,117 loci of which 2,417 have only one EST
mapped to them (data not shown).
In order to determine whether our technique quantita-
tively measures transcript abundance, we compared our
EST library to two SAGE libraries of R1881 treated LNCaP
cells [15,16]. These two combined libraries have approxi-
A histogram showing the number of gene loci hit by a given number of ESTs Figure 1
A histogram showing the number of gene loci hit by a given number of ESTs.
Table 2: Top 10 most abundant transcripts in androgen-stimulated LNCaP cells by EST count.
Count Ensembl Gene ID Description
22377 ENSG00000198899* ATP synthase a chain (EC 3.6.3.14) (ATPase protein 6).
7595 ENSG00000198916* No description
3200 ENSG00000148341 SH3 domain GRB2-like protein B2 (Endophilin B2).
2112 ENSG00000198804* Cytochrome c oxidase subunit 1 (EC 1.9.3.1) (Cytochrome c oxidase polypeptide I).
1678 ENSG00000198886* NADH-ubiquinone oxidoreductase chain 4 (EC 1.6.5.3) (NADH dehydrogenase subunit 4).
1628 ENSG00000198938* Cytochrome c oxidase subunit 3 (EC 1.9.3.1) (Cytochrome c oxidase polypeptide III).
1392 ENSG00000186063 No description
1311 ENSG00000198763* NADH-ubiquinone oxidoreductase chain 2 (EC 1.6.5.3) (NADH dehydrogenase subunit 2).
1201 ENSG00000170421 Keratin, type II cytoskeletal 8 (Cytokeratin 8) (K8) (CK 8).
1088 ENSG00000198744* No description
* indicates mitochondrial genesBMC Genomics 2006, 7:246 http://www.biomedcentral.com/1471-2164/7/246
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mately 28,000 unique tags that we mapped unambigu-
ously to 1,050 genes using DiscoverySpace [17].
Calculating the Pearson coefficient for all 9,173 genes
gives a correlation value of 0.40. This value increases to
0.45 if we only consider genes that had at least one SAGE
tag. Of our 10 most abundant genes, 3
(ENSG00000198899, 198886, 198763) are represented
in the top 15 most abundant genes in the SAGE library. By
reducing our stringency on which tags are deemed ambig-
uous we can successfully map an additional 3 genes of our
top ten genes to the top 15 most abundant genes in the
SAGE library.
We studied the representation of the ESTs across known
spliced transcripts (Figure 2). From this experiment, we
observe four types of sequencing bias. The first favours the
positive strand (coding) of the transcript. The second bias
is seen at the 5' and 3' ends of the transcript. This occurs
because the ends of a given transcript are readily available
for sequencing, even if fragmentation of the cDNA is
incomplete during the sample preparation (Methods).
The increased representation of sequences in the mid-
range of the transcript arises, almost entirely, to transcripts
having lengths shorter than 1,200 bp. We found that such
transcripts generally shear near the centre of the sequence
(data not shown). Lastly, there is a general bias to the 3'
end of the transcript that is likely due to incomplete cDNA
synthesis across the entire length of the RNA transcript.
We investigated the ability of this approach to identify
alternatively spliced transcripts within the mRNA popula-
tion. By using BLAT [18] to map reads which showed
good alignment to the transcriptome, but poor alignment
at either end of the read, we discovered 25 (Table 3) pre-
viously unreported splice junctions that begin and end in
a previously annotated exon and 106 novel alternative
splice variants that map from a known exon and splice
into intronic sequence. For all alternate splices, save 2, the
event was demonstrated by a single EST. Figure 3 shows an
alternative splicing event within the gene coding for Brain
Protein I3 (BRI3) that causes a 40 base pair insertion
between exons 1 and 2. This frame-shift occurs upstream
of the transmembrane regions of the protein, as predicted
by Ensembl [19], and although it does not cause a prema-
ture stop in the coding sequence, it eliminates the trans-
membrane domains of the protein as determined by
InterProScan [20]. Interestingly, disruption of BRI3 has
A histogram showing the start of EST alignments to human transcript sequences (length > 500) Figure 2
A histogram showing the start of EST alignments to human transcript sequences (length > 500). Position is given 
as a percentage of the length of the transcript. ESTs which align to the positive or negative strands of the cDNA are shown in 
light or dark grey, respectively.BMC Genomics 2006, 7:246 http://www.biomedcentral.com/1471-2164/7/246
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been implicated in tumor necrosis factor alpha (TNF-α)
induced apoptosis resistance [21].
In areas where the base quality, as determined by the 454
sequencer, was exceptionally high, we utilized the EST
data to detect high quality discrepancies (HQDs) in the
LNCaP transcriptome. In this analysis, we required that
discrepancies have a phred-like score >80 in order to be
considered significant. This score threshold is set a such a
level that we would require, at minimum, 3 sequences to
confirm the presence of a HQD. Using this stringent
approach we discovered 1,479 HQDs of which 86 (5.8%)
were present in Ensembl's variations database [3], 29
showed variations at the same position but to a different
base, and 1,364 were not described in Ensembl. For each
HQD type, the mean and median base quality score were
calculated (see Methods). The mean and median scores
for confirmable HQDs are significantly higher (p ≤ 0.02)
than for unconfirmable HDQs (Table 4). Although we do
not dismiss all of the unconfirmable 1,393 HQDs as spu-
rious, even under such an hypothesis, a significant (p ≤ 10-
45) enrichment of characterized variations is found, as
compared to random sampling.
We also used the ESTs for the discovery of unannontated
genes. Of the 40,373 ESTs that did not map to the known
human transcriptome at high stringency, 19,392 (48.0%)
were successfully mapped to the entire human genome
sequence at high confidence (p ≤ 5 × 10-6). Of these, 9,488
(48.9%) map mostly or entirely to an intron. The remain-
Table 3: 25 novel alternative splicing events in androgen-stimulated LNCaP cells
Ensembl ID Name Description Splice description
ENST00000248342 eIF3k Eukaryotic translation initiation factor 3 subunit 
12
25 bp deletion of 3' end of exon 1
ENST00000207437 MLEY_HUMAN Myosin light chain 1, slow-twitch muscle A 
isoform
64 bp deletion of 5' end of exon 2 (contained in 5' 
UTR)
ENST00000330964 RPS27L 40S ribosomal protein S27-like protein Deleteion of retained intron in exon 1 (54 bp of 
coding sequence)
ENST00000358666 UBL5 Ubiquitin-like protein 5 121 bp deletion of 3' end of exon 1 (contained in 
5' UTR)
ENST00000262746 PRDX1 Peroxiredoxin 1 227 bp deletion of 3' end of exon 1 (contained in 
5' UTR)
ENST00000297290 BRI3 Brain protein I3 See Figure 3.
ENST00000341480 MED18 Mediator of RNA polymerase II transcription, 
subunit 18 homolog
Deletion of retained intron in exon 3 (entriely 
contained in 3' UTR)
ENST00000270799 RPL11 60S ribosomal protein L11 89 bp deletion of 3' end of exon 2 and 103 bp 
deletion of 5' end of exon 5
ENST00000303553 NDUFA3 NADH-ubiquinone oxidoreductase B9 subunit Deletion of 45 bp retained intron in exon 4
ENST00000222673 OGDH (MTpc) 2-oxoglutarate dehydrogenase E1 component, 
mitochondrial precursor
Deletion of 210 bp retained intron (contained in 
3' UTR)
ENST00000361643 This gene can be found on Chromosome MT at location 1,673–3,230. Deletion of 47 bps
ENST00000361390 ROPN1B (MT) NADH-ubiquinone oxidoreductase chain 1 Deletion of 648 bp
ENST00000302192 Q8WUV6_HUMAN Podocalyxin-like 2 Deletion of 363 bp retained intron in exon 8
ENST00000361643 This gene can be found on Chromosome MT at location 1,673–3,230. Deletion of 1268 bps
ENST00000261798 CSNK1A1 Casein kinase I, alpha isoform Insertion of unknown length between exons 4 
and 5
ENST00000339892 This gene can be found on Chromosome 1 at location 234,416,172–
234,416,946.
Deletion of 42 bp in 3' UTR
ENST00000322297 OAZ1 Ornithine decarboxylase antizyme Deletion of last 4 coding bp and 54 bp of 3' UTR
ENST00000224892 LHPP Phospholysine phosphohistidine inorganic 
pyrophosphate phosphatase
Deletion of last 105 bp of exon 1, exons 2–6, and 
first 608 bp of exon 7
ENST00000361381 NU4M_HUMAN 
(MT)
NADH-ubiquinone oxidoreductase chain 4 Deletion of 152 bp
ENST00000358666 UBL5 Ubiquitin-like protein 5 80 bp deletion of 3' end of exon 1 (contained in 5' 
UTR)
ENST00000239377 PCMT1 Protein-L-isoaspartate(D-aspartate) O-
methyltransferase
47 bp deletion of 3' end of exon 7 (10 bp coding, 
remainder in 5' UTR)
ENST00000361899 ATP6 (MT) ATPase protein 6 Deletion of 91 bp
ENST00000291565 PDXK Pyridoxal kinase Deletion of 281 bp retained intron (contained in 
3' UTR)
ENST00000308964 This gene can be found on Chromosome 19 at location 60,851,213–
60,856,333.
42 bp deletion of 3' end of exon 2, exons 3–5, and 
first 541 bp of exon 6
ENST00000361390 ROPN1B(MT) NADH-ubiquinone oxidoreductase chain 1 Deletion of 346 bpBMC Genomics 2006, 7:246 http://www.biomedcentral.com/1471-2164/7/246
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ing 9,904 ESTs map intergenically, that is, to a region that
is not known or predicted to contain an ORF. Further,
1,900 (19.2%) of these ESTs map to a region where there
is no existing alignment feature in Ensembl (EST gene, or
EST) and 380 (3.8%) align at least 20 Kbp away from a
known gene.
Of the 40,373 reads, 20,981 failed to map to the human
genome at p ≤ 5 × 10-6. Figure 4 shows the distribution of
ESTs that fail to map successfully to the human genome or
transcriptome at various p-value thresholds. At p ≤ 0.05,
9,585 reads remain unmapped.
The 9,585 ESTs that failed to map to the human genome
were then aligned to sequences in GenBank-nt (Dec 5th,
2005). 7,643 failed to map with a p-value ≤ 0.05, 605
reads mapped most strongly to human sequences and 587
reads were mapped to other organisms (Table 5). The 605
human sequences that failed to map to the human
genome/transcriptome were missed for 2 reasons. First,
because of the different nucleotide frequencies in the two
databases, ESTs that have low complexity, and therefore
high p-values, when mapped to the human genome (or
transcriptome) have lower p-values when mapped to Gen-
Bank-nt. Second, the GenBank-nt database contained
ESTs with splicing patterns not represented in the current
Ensembl transcript annotation. Therefore, the ESTs that
map to exon-exon junctions in these speculated genes will
also have poor p-values. The 587 reads which were
mapped to other organisms are a product of contamina-
tion of the sample. Although the contamination could
have occurred before cDNA production, the nature of the
contaminants suggests that this most likely occurred in
the 454 nebulization process. The 7,643 remaining ESTs
are almost certainly the product of poor quality sequenc-
ing. Although their quality values are not significantly dif-
ferent from the other reads, they are markedly shorter
(average length of ~86 nt) which reduces the minimum
possible p-value for these sequences.
Conclusion
The data reported here show that massively parallel
sequencing-by-synthesis methods can be used to success-
fully survey a transcriptome. Of the top 10 most abundant
transcripts, 7 are involved with energy production and are
located on the mitochondrial genome (Table 2). The over
representation of metabolic genes may be indicative of the
high energy requirements of the cancerous cell. Interest-
ingly, 8 of the 25 novel splicing events listed in Table 3
also occur in genes directly involved with mitochondria
and/or energy production, whereas 4 others are involved
in translation or transcription and may have multiple
effects on the cell. Further, we were able to identify the
expression of over 10,117 different genes (p ≤ 0.05). Of
these genes, approximately one-third are detected by only
one or two ESTs (Figure 1), showing a low level of redun-
dancy in the library and indicating that further sequence
sampling likely would determine the transcription of sig-
nificantly more gene loci.
This compares favourably to Affymetrix microarray exper-
iments done with LNCaP, which typically find between
two and eight thousand genes (Gene Expression Omibus
(GEO); [22,23]; January 16th, 2006). A specific study of
LNCaP cell expression was carried out by Oudes et al. [24]
using both the Affymetrix profiling platform [25] and
Massively Parallel Signature sequencing (MPSS) [26]. In
this analysis, 9,841 genes were identified as being
expressed using the Affymetrix technology (p ≤ 0.04) and
7,863 using MPSS. In total, Oudes et al. identified 9,841
genes expressed in LNCaP. Our approach compares
favourably to MPSS, finding 16.6% more genes. Although
we find 668 fewer genes than the Affymetrix approach at
high stringency, using a lower BLAST alignment strin-
gency (p ≤ 0.05), we discover 276 more genes than by the
microarray-based approach.
Alternative splicing of Brain Protein I3 (ENSG00000164713) showing a short insertion between two exons Figure 3
Alternative splicing of Brain Protein I3 (ENSG00000164713) showing a short insertion between two exons. 5' 
and 3' ends of two exons are shown in black text, interspaced by an intron (full sequence not shown) in orange. Base positions 
where the EST aligns to the transcript indicated with bold and italic type. The 40 base insertion is high-lighted in blue.
Table 4: The HQD count, mean and median phred scores and 
the HQD count
HQD Type Count Mean Median Count > 400
Confirmable 86 342.4 163 16
Novel 1364 270.2 136 175
Other 29 233.2 122 4
Counts collected for phred scores > 400 for each of the three HDQ 
classes: those confirmable by Ensembl, those that occur in positions 
with no known variations, and those that have incorrect mutations at 
positions with known variations ("Other").BMC Genomics 2006, 7:246 http://www.biomedcentral.com/1471-2164/7/246
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We were able to identify 25 novel alternative exon splicing
events from 20 MB of data in a stringent, high-throughput
manner. We also discovered over four thousand ESTs that
are entirely or partially intronic. These may originate from
unprocessed mRNA or may represent novel or extended
exons. Although it is not possible to fully determine the
exact sequence of any of these interesting transcripts from
454 reads, this technique does identify transcripts which
could be PCR-amplified and sequenced in their entirety.
Of the ~9,000 detected genes 76 are directly described as
being involved with cancer or the prostate. The most
highly expressed prostate cancer gene is Prostate Specific
Androgen (PSA) and the most highly expressed cancer
specific gene is Mindin. Both genes have been previously
identified as strong prostate cancer markers [27,28] and
both are in the top 40 most abundant genes in our EST
library (data not shown). This would seem to indicate that
our approach is capable of identifying genes important to
prostate cancer pathology.
With respect to using 454 sequencing to measure tran-
script abundance, our results correlate modestly to those
of SAGE, having Pearson coefficients between 0.4 and
0.45. However, these values are not significantly lower
than correlations between long and short SAGE or SAGE
and Affymetrix chips which generally lie between 0.4 and
0.65 [29]. The reason for our low correlation coefficients
is likely due to a combination of factors. Most notably is
that the long reads produced by 454 allow more tags to be
mapped unambiguously to a gene as compared to SAGE
where the short ESTs are much more likely to align to mul-
tiple loci. Further, the number of tags produced for a given
transcript by 454 will depend on transcript length and
shearing efficiency as well as transcript abundance. These
latter factors make compensating for biases in transcript
abundance difficult.
From the approximately 300,000 base pairs of EST
sequence with a total phred-like score > 80, as assessed by
the 454 base calling software, we determined approxi-
A histogram of ESTs that fail to map to the human genome at various p-values Figure 4
A histogram of ESTs that fail to map to the human genome at various p-values.BMC Genomics 2006, 7:246 http://www.biomedcentral.com/1471-2164/7/246
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mately 1,500 high-quality discrepancies with respect to
the human reference sequence (Table 4). This represents
approximately one polymorphism per 200 base pairs.
This rate is approximately 3–4 times higher than would be
expected from the sequencing of DNA from a normal
human diploid source [30]. This increased rate of poly-
morphism can possibly be attributed to the genomic
instability and loss of DNA repair mechanisms that would
have contributed to the original malignancy [31] as well
as the number of passages the cell-line would have under-
gone since the original isolation in 1977, and during
which additional mutations would have accrued [11].
Lastly, we were able to map 1,900 ESTs to regions in the
human genome where there are neither genes nor other
alignment features, such as ESTs (Table 1). This is consist-
ent with studies using the Affymetrix technology which
determined that 49% of transcribed bases determined on
human chromosomes 21 and 22 fell outside regions con-
taining a gene annotation [32].
This analysis also revealed the bias that occurs when
sequencing short sequences of DNA by 454 sequencing
(Figure 2). Due to poor or inconsistent nebulization of
the cDNA sample, sequencing occurs more frequently at
the 3' and 5' ends than at the middle of the DNA strand,
and this gives uneven profiling of the underlying tran-
scriptome. The 3' bias is compounded by incomplete (i.e.
not full length) cDNA synthesis, which is known to bias
the 3' ends of transcripts. Lastly, there is a bias to the cod-
ing strand of the transcript and the exact mechanism
underlying this observation remains unclear. Fortunately,
however, this last form of bias has little effect on the pos-
sibility of observing alternate splicing events or HDQs in
a transcript. The former biases can likely be overcome by
using an alternate method of fragmenting the cDNA such
as random-hexamer primed PCR or possibly nebulizing to
a smaller fragment size. We also discovered a minor diffi-
culty with contaminating DNA in the sample preparation
(Table 5). This highlights the sensitivity of 454 sequenc-
ing as well as the need to keep sample preparation clean
and to be stringent when aligning sequence data to a tar-
get organism.
Much of the complexity in our analysis was due to the pro-
pensity of 454 sequencing to insert or delete bases in
homopolymeric nucleotide runs [10]. This caused exces-
sive penalties for gapping and other difficulties in the
alignments when using a traditional alignment tool such
as BLAST. Alternatively, BLAT tended to over-insert large
gaps in the alignments because it suspected every inser-
tion or deletion in the sequence to potentially be the start
of an intron. Further use of this technology for transcrip-
tional profiling would require the development of a tool,
similar to BLAT, which does not greatly penalize gaps that
begin in a homopolymeric region of the sequence and as
a consequence, provides better prediction of intron-exon
boundaries.
This work has shown that high-throughput sequencing
using the 454 sequencing-by-synthesis approach is able to
profile transcript abundance, and to discover nucleotide
discrepancies and novel transcript splicing events.
Methods
Cell culture and mRNA preparation
LNCaP human prostate cancer cells (American Type Cul-
ture Collection®; Bethesda, MD) were maintained in
RPMI-1640 media (StemCell Technologies; Vancouver,
BC) supplemented with 10% fetal bovine serum (FBS;
StemCell Technologies) and incubated at 37°C with 5%
CO2. Cells at passage 38 were plated at a density of
approximately 4 × 106 cells per T175 flask. Cells were
serum-starved for 48 hours prior to treatment for 16 hours
with 10 nM R1881 (PerkinElmer; Woodbridge, Canada).
Cells were harvested and total RNA was extracted from the
cells using TRIZOL® Reagent (Invitrogen™ Life Technolo-
gies, Carlsbad, CA) following the manufacturer's instruc-
tions.
cDNA preparation
RNA was assayed for quality and quantified using an Agi-
lent 2100 Bioanalyzer (Agilent Technologies, Mississauga,
ON) and RNA 6000 Nano LabChip kit (Caliper Technol-
ogies, Hopkinton, MA). Contaminating genomic DNA
was removed from 1 mg of total RNA by DNAse1 treat-
ment using DNAfree (Ambion, Austin, TX) following the
manufacture's instructions. mRNA was isolated from total
RNA using the MACS mRNA Kit (Miltenyi Biotec, Auburn,
CA) following the manufacture's instructions with the
exception of two additional washes prior to elution and a
3% final yield of mRNA (28 ug). cDNA was prepared from
12 ug of mRNA using the SuperScript Choice cDNA syn-
thesis kit following the manufacture's instructions (Invit-
rogen Life Technologies, Carlsbad, CA). The resulting 7.1
Table 5: Idetification of contamination of 454 EST data
Species of Origin Number of ESTs
E. coli 133
Enterococcus sp. 86
Staphylococcus sp. 78
Cloning vector 42
P. marinus (Sea Lamprey) 37
Other 211
Total 587BMC Genomics 2006, 7:246 http://www.biomedcentral.com/1471-2164/7/246
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ug of cDNA was concentrated to ~300 ng/ul by lyophiliza-
tion prior to 454 sequencing.
454 sequencing
In preparation for 454 sequencing, the cDNA sample was
nebulized to a mean fragment size of 600 ± 50 bp, end
repaired and adapter ligated according to the standard
procedures described previously [10]. After streptavidin
bead enrichment and DNA denaturation, we recovered
5.21 E+10 single-stranded molecules/ul with an average
size of 620 ± 50 bp that were titrated onto derivatized
Sepharose beads and then amplified by emulsion PCR. A
second streptavidin bead enrichment followed emulsion
breaking, the bead-attached DNAs were denatured with
NaOH, and sequencing primers were annealed. Two 454
sequencing runs were obtained from this library – the first
on a 40 × 75 Picotitreplate™ (PTP) and the second on a 70
× 75 PTP. We followed standard post-run bioinformatics
processing on the 454 platform to determine reads that
passed various quality filters. These reads were used in our
downstream analysis, as described.
Sequence analysis
Sequences were first trimmed of low quality bases which
can occur at the end of reads using trim2 (-M 10) [12]. The
reads where then mapped to the human transcriptome
(Ensembl cDNA, November 8th 2005) using wuBLAST
[13] (version 2.0 May 10th, 2005) (-V100 -B100 -W25).
BLAST hits with a p-value ≤ 9 × 10-7, which corresponds
approximately to a 60 base pair contiguous perfect match
in the data set, were considered to be successful hits
against the transcriptome.
In order to determine that our mappings were real, we
aligned with wuBLAST the lowest scoring hits (9 × 10-8 ≤
p < 9 × 10-7), 3,784 in total, against the GenBank-nt data-
base. Of these 3,448 (91.1%) hit a human sequence most
strongly. 191 (5.0%) hit a primate, usually with only 1 or
2 more matching bases than in the human alignment and
the remaining 145 (3.8%) hit other organisms.
Of the reads that successfully hit the transcriptome those
that were not aligned within 25 bp or more of the 3'- or 5'-
end of the EST were considered gapped and were aligned
against a collection of transcription units (Ensembl tran-
script, November 8th, 2005) using BLAT [18]. BLAT hits
were considered better if BLAT extended the alignment of
the EST by at least 25 bps and at least 25 bps were aligned
on either side of any large gaps, if present, in the align-
ment (presumed to be intronic sequence). The BLAT hits
were then evaluated on whether they over/under-ran a
transcription unit, over/under-ran an exon, mapped from
one exon to another, or mapped from an exon to an
intron.
Sequences that did not map to the human transcriptome
were then aligned with wuBLAST (-V100 -B100 -W15) to
the human genome. Lower values of W (wordsize) were
attempted but made little difference to the number of
ESTs mapped (data not shown). The positions of signifi-
cant hits (p ≤ 5 × 10-6), which correspond approximately
to a 60 base pair contiguous perfect match in the data set,
with respect to genes, introns, exons, ESTs and other DNA
alignment features, were determined using the perl
Ensembl API [33] (version 35) and Ensembl database
(version 35). Reads that did not map against the human
genome (p ≤ 0.05) were then aligned against the GenBank
nucleotide database (Dec 5th, 2005) with wuBLAST.
HQD analysis
High quality discrepancies (HQDs) were discovered by
first using the alignments of ESTs to the transcriptome
(described above). However, only very high quality align-
ments were kept, such that no alignment contained more
than 3 mismatches, nor more than 9 gap positions. For
every possible nucleotide X = (A or C or G or T), at every
position Y, in a transcript, the number of ESTs that pos-
sessed base X at position Y in their alignment was calcu-
lated along with the combined phred-like [34,35] quality
score for that base. The combined phred-like score is the
sum of all phred scores from each EST that contributes to
X at Y. A discrepancy was defined as any mismatch in an
alignment. The discrepancy was considered high quality if
the combined phred-like score for that base was >80. For
example, suppose in a given transcript that we expect an
'A' at position 1000. If 4 ESTs align to this transcript over-
top the 1000th base, each with associated scores as fol-
lows: A (30), C (25), C (30), C(30), then at this position
we have the canonical A with a score of 30, and a high
quality discrepancy 'C' with a score of 85.
Each HQD was either confirmed by its presence in
Ensembl's variance database, or marked as speculative
due to its absence in Ensembl. The probability of observ-
ing 86 or more confirmable HQDs out of 1,479 total
HQDs is given by the binomial distribution.
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